Before any cell or gene therapy candidate can be tested in human patients in the United States, its developer must clear a regulatory milestone known as the Investigational New Drug application, or IND. For CGT specifically, this process carries unique requirements that distinguish it meaningfully from the IND pathway traditional small-molecule or biologic developers navigate.
What Is the Purpose of the IND Application?
An IND application is the formal mechanism by which a company requests FDA authorization to begin testing an investigational therapy in human clinical trials. The application has to demonstrate, through preclinical data, that the therapy is reasonably safe to test in humans, and it has to provide a detailed plan for how the proposed clinical trial will be conducted, monitored, and reported. For any therapeutic candidate, this represents the formal transition point between laboratory and animal research and human clinical investigation — the point at which a candidate therapy first becomes something tested directly in patients.
Why Does CGT Require Additional IND Considerations Beyond Traditional Therapies?
CGT IND applications require several categories of data and justification that don’t have a direct equivalent in traditional pharmaceutical IND submissions, reflecting the unique nature of these therapies as living, biological products rather than defined chemical compounds. Chemistry, manufacturing, and controls documentation for a CGT product has to address the inherent variability of working with living cells or viral vectors — manufacturing consistency questions that simply don’t arise the same way for a small-molecule compound with a fixed, reproducible chemical structure.
An Immunogenicity Risk Assessment is required as part of the CGT IND package specifically, addressing the therapy’s potential to provoke an immune response — supporting data for this assessment depends on the specific drug, its mechanism of action, administration route and frequency, relevant patient factors, and the disease indication being targeted. Long-term follow-up planning is another CGT-specific IND requirement: because gene therapies in particular can produce effects that persist or even change over extended periods, sponsors typically need to propose how patients will be monitored well beyond the active treatment period, sometimes for fifteen years or longer depending on the specific therapy’s risk profile.
What Do FDA Guidance Documents Actually Require Sponsors to Demonstrate?
FDA guidance for CGT IND packages organizes around three sequential areas of focus, each demanding a different kind of evidence: proof of concept, toxicology, and post-administration monitoring. Proof of concept data centers on demonstrating biological activity — evidence such as growth factor secretion, a defined immunological response profile, or expression of a targeted neurotransmitter, depending on the specific therapy’s mechanism. Because in vitro data alone is generally considered insufficient to predict how a CGT product will behave physiologically once administered, the FDA encourages the use of animal models of disease or injury specifically to characterize morphological changes alongside the functional and behavioral changes those models can reveal — evidence that in vitro testing simply cannot generate on its own.
Toxicology data draws on both in vivo and in vitro assay results to inform preclinical toxicology study design, and sponsors are expected to provide enough information to identify, characterize, and quantify potential local toxicities, potential systemic toxicities, the onset timing of any observed toxicities — distinguishing acute from delayed effects — whether any observed toxicity appears resolvable over time, and how toxicity findings relate to the specific product dose administered.
Post-administration monitoring represents the area where CGT diverges most clearly from traditional pharmaceutical IND expectations. Conventional IND filings typically characterize a candidate’s absorption, distribution, metabolism, and excretion — the ADME framework standard across traditional drug development. That framework simply doesn’t map onto living cell and gene therapy products, so the FDA instead expects sponsors to characterize a different set of parameters: distribution within the body, tracked through methods like PCR, immunohistochemistry, or radio-labeled imaging; differentiation and integration, assessed through morphology and phenotype; survival and engraftment, evaluated for biocompatibility; tumorigenicity, assessed through kinetic profiles, expressed genes, and direct monitoring for tumor formation; and safety, covering adverse reactions, off-target effects, viral replication levels, and unintended activation of target cells.
How Has the FDA’s Approach to CGT INDs Evolved?
The FDA has actively worked to build regulatory infrastructure specific to CGT’s unique development challenges, rather than simply applying frameworks built for traditional pharmaceuticals to a fundamentally different category of therapeutic. The Regenerative Medicine Advanced Therapy designation, available to qualifying CGT candidates addressing serious or life-threatening conditions with preliminary clinical evidence of meaningful therapeutic benefit, provides enhanced FDA engagement throughout development — including more frequent interactions with the review division and eligibility for accelerated approval pathways. By the mid-2020s, more than 40 percent of active CGT development programs had received this designation, and RMAT-designated programs have generally moved through development meaningfully faster than non-designated programs facing comparable scientific and regulatory questions.
This evolving regulatory posture reflects an FDA actively trying to keep pace with a field developing faster than its regulatory frameworks were originally built to accommodate — adjusting guidance, creating new designations, and engaging earlier and more frequently with sponsors than would be typical for a more established therapeutic category with settled regulatory expectations.
What Does the IND Review Timeline Actually Look Like?
Once a complete IND application is submitted, the FDA has 30 calendar days to review it before a sponsor may begin the proposed clinical trial — a statutory clock that applies to CGT INDs the same way it applies to any other IND submission. During this 30-day window, the FDA can respond in one of several ways: allowing the trial to proceed as proposed, placing the IND on clinical hold pending additional information or modifications, or, less commonly within the initial window, requesting changes that don’t rise to the level of a formal hold but still need to be addressed before enrollment begins.
Clinical holds carry particular significance in CGT specifically, given how often CGT IND packages raise genuinely novel safety or manufacturing questions the FDA hasn’t previously evaluated for a similar product. A hold is not necessarily a negative signal about a therapy’s ultimate viability — it often reflects the FDA working through legitimately new scientific territory alongside the sponsor, particularly for first-in-class modalities where no directly comparable approved product yet exists. Sponsors who have engaged FDA early, through pre-IND meetings and ongoing dialogue, generally experience fewer holds and faster resolution when holds do occur, since much of the underlying scientific and regulatory question has already been worked through collaboratively before the formal IND clock even started running.
What Should Sponsors Expect When Preparing a CGT IND?
Sponsors preparing a CGT IND submission benefit from engaging with the FDA earlier in development than may feel intuitive coming from a traditional pharmaceutical development background, given how much of the CGT-specific guidance continues to evolve and how much benefit early FDA interaction can provide in clarifying expectations for a given therapy’s specific risk profile. Pre-IND meetings, where a sponsor can discuss a proposed development plan with FDA reviewers before formally submitting, have become a particularly valuable tool in CGT development specifically, given how much variability exists across different CGT modalities in what data and justification a complete IND package actually requires.
Sponsors should also expect that even within the CGT-specific framework described here, the precise data requirements for a given IND submission will be shaped heavily by the specific modality, vector, target indication, and patient population involved — there is no single template IND package that applies uniformly across all CGT candidates, which is itself a direct consequence of how diverse and how quickly evolving the broader CGT field remains.